“Dysautonomia is probably significantly more common than we realize,” says Jeremy Cutsforth-Gregory, a neurologist at Mayo Clinic in Rochester, Minnesota. “I think it’s significantly underdiagnosed.” In about half of POTS cases, he adds, the patient’s disease grows out of the immune response to an infection.
Ryan Cooley, a doctor and co-director of the Dysautonomia Center at Aurora Medical Center in Grafton, says detecting the disorder is especially challenging because “typically there isn’t a dominant symptom or physical finding.”
Perhaps the most common clue to the disorder is that patients find that when they stand up from a chair their heart races and they feel light-headed.
AHEAD OF the 2020 American presidential election, John Prideaux, The Economist‘s US editor, talks to Bill Weld, a former governor of Massachusetts, Joe Walsh, a talk radio host and former Illinois congressman, and Mark Sanford, a former governor of South Carolina. While Donald Trump enjoys near 90% approval ratings among his party, can anyone challenge him for the Republican presidential nomination? And how has he changed what it means to be a Republican?
Wall Street Journal corporate bureau chief Marcelo Prince explains the competition between retailers Amazon, Target and Walmart to provide one-day shipping to customers during the holiday season.
The National Institutes of Health’s largest loan repayment program was conceived to help scientists pay off school debts without relying on industry funding. But a close examination of the program by investigative correspondent Charles Piller has revealed that many participants are taking money from the government to repay their loans, while at the same time taking payments from pharmaceutical companies. Piller joins Host Sarah Crespi to talk about the steps he took to uncover this double dipping and why ethicists say this a conflict of interest.
There can be few applications of digital technology more worthwhile than saving lives, but integrating digital technology into healthcare systems is uniquely complex. This episode provides an introduction to some of the challenges that healthcare providers face in their pursuit of digital innovation, and explores some of the paths forward.
Host Pete Swabey is joined by Professor Ann Blandford, deputy director for digital health at the UCL Institute of Healthcare Engineering; by Jackie Hunter, chief executive, clinical programmes & strategic relationships at AI-powered drug development firm Benevolent.AI; and by Elizabeth Sukkar, managing editor and global editorial lead for healthcare at The EIU. Sponsored by DXC Technology.
Medicare negotiation of prescription-drug prices would bring U.S. government policies in line with those of other high-income countries, and the idea is popular with both the public and policy analysts. But it would represent a sea change for pharmaceutical firms, which will maintain that any threat to their pricing power will slow innovation.
Negotiating prices of 10 too-little drugs and 10 too-late drugs to levels currently paid in the United Kingdom would produce about $26.8 billion in savings in 2019 alone, most of which ($25.9 billion) would come from savings on drugs in the latter category. Over time, the drugs included could change. For instance, in 2020 this category might include Revlimid (lenalidomide), which generated $6.5 billion in 2018 U.S. sales; its price in the United Kingdom is 32% of that in the United States.
Americans all along the political spectrum favor allowing Medicare to negotiate the prices it pays for prescription drugs.1 In September, House Speaker Nancy Pelosi (D-CA) introduced what is now called the Elijah E. Cummings Lower Drug Costs Now Act of 2019 (H.R. 3), and the bill would have Medicare do just that.
Although there are draft pieces of legislation and regulation that take aim at the rising cost of drugs, H.R. 3 is the legislative tip of the spear for price negotiation. If it became law, Medicare would target drugs that claim the largest share of the health care budget and that face limited competition from generics or biosimilars. I propose an alternative set of drugs for price negotiation: those that have too little evidence to support full approval or are too late in their life cycle to justify continued high prices.
MICHAEL BLOOMBERG, the billionaire former mayor of New York, has announced he is running for president. But he is late to join the race and not very popular with Democratic primary voters. We also look at TikTok, a wildly successful video-sharing app that some see as a threat to security in the Western world. And much of Switzerland is up in arms—about the reliability of the country’s coffee supply. Runtime: 20 min
Listen to the latest science updated, brought to you by Nick Howe and Shamini Bundell. This week, delving into the results of the latest graduate student survey, and assessing ageism in science fiction literature.
In this episode:
00:45 The graduate student experience
The results of Nature’s 2019 PhD survey are in. David Payne, Nature’s Chief Careers Editor, takes us through them. Nature’s PhD survey collection
An infinite number of things happen; we bring structure and meaning to the world by making art and telling stories about it. Every work of literature created by human beings comes out of an historical and cultural context, and drawing connections between art and its context can be illuminating for both. Today’s guest, Stephen Greenblatt, is one of the world’s most celebrated literary scholars, famous for helping to establish the New Historicism school of criticism, which he also refers to as “cultural poetics.” We talk about how art becomes entangled with the politics of its day, and how we can learn about ourselves and other cultures by engaging with stories and their milieu.
One of the most successful artists of the Italian Renaissance, Titian was the master of the sixteenth-century Venetian school and admired by his royal patrons and fellow artists alike. Several of his contemporaries, including the authors and art theorists Giorgio Vasari, Francesco Priscianese, Pietro Aretino, and Ludovico Dolce, wrote accounts of Titian’s life and work.
In this episode, Getty assistant curator of paintings Laura Llewellyn discusses what these “lives” teach us about Titian and the artistic debates and rivalries of his time. All of these biographies are gathered together in Lives of Titian, recently published by the Getty as part of our Lives of the Artists series.